Engineered Monoacylglycerol Lipase for Detergent-Free Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge lies in obtaining well-ordered protein crystals of monoacylglycerol lipase (MGLL) suitable for high-resolution X-ray crystallography, as detergent-solubilized MGLL is prone to aggregation and difficult to crystallize, hindering the discovery of selective inhibitors and structure-based drug design.
Innovation Solution
Engineered forms of MGLL with selective point mutations in the cap-domain, such as mutating hydrophobic residues like Leucine to Serine, Glutamine, or Arginine, and surface lysine residues to Alanine, which do not require detergents for purification, allowing for stable monomeric behavior and improved crystallization, enabling atomic resolution structure determination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If detergent-solubilized MGLL is used for purification, then the protein can be solubilized and purified, but it becomes prone to aggregation and difficult to crystallize
Solution Approach 1:
The patent applies parameter changes by mutating specific amino acid residues in the cap-domain of MGLL (such as hydrophobic residues like Leucine to Serine, Glutamine, or Arginine, and surface lysine residues to Alanine). These mutations alter the physical and chemical parameters of the protein, specifically reducing hydrophobicity and improving solubility, thereby enabling the protein to be purified without detergents and to form well-ordered crystals suitable for high-resolution X-ray crystallography
Solution Approach 2:
The patent applies local quality by making selective point mutations only in the cap-domain region of MGLL, rather than throughout the entire protein. This localized modification approach allows the protein to maintain its overall structure and function while improving specific properties (solubility and crystallization capability) in the problematic cap-domain region
2Quantity of substance
If hydrophobic residues in cap-domain are mutated to polar residues, then solubility improves and detergent requirement is eliminated, but protein structure may be altered
Solution Approach 1:
The patent carefully selects amino acid substitutions that change local polarity parameters while preserving overall protein stability. By replacing hydrophobic residues with polar residues (Serine, Glutamine, Arginine) and surface lysine residues with Alanine in the cap-domain, the protein achieves improved solubility and detergent-free purification while maintaining structural integrity suitable for crystallization
Solution Approach 2:
The mutations are localized to the cap-domain, allowing the rest of the protein structure to remain unchanged and maintain its native conformation. This localized modification ensures that the catalytic domain and other functional regions retain their structural integrity while the cap-domain gains improved solubility properties
3Manufacturing precision
If point mutations are introduced to improve crystallization, then crystal quality improves, but the process complexity increases
Solution Approach 1:
The patent employs selective point mutations focused specifically on the cap-domain region, which contains hydrophobic residues and surface lysine residues known to affect crystallization. By limiting mutations to this specific region rather than the entire protein, the engineering complexity is managed while achieving significant improvements in crystal quality and order
Solution Approach 2:
The patent systematically alters specific amino acid parameters (hydrophobicity, surface charge) in the cap-domain to optimize crystallization properties. These targeted parameter changes produce well-ordered crystals suitable for high-resolution X-ray crystallography without requiring extensive protein engineering throughout the entire protein structure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These engineered forms facilitate the identification of MGLL inhibitors through high-throughput screening and provide a crystal structure suitable for structure-based drug design, enhancing the understanding of MGLL's mechanism and potential therapeutic targeting.
Implementation Method 1
The X-ray diffraction patterns of the crystals of the present invention are of sufficient resolution so that the three-dimensional structure of MGLL can be determined at atomic resolution
Implementation Method 2
The X-ray diffraction patterns of the crystals of the present invention are of sufficient resolution so that the three-dimensional structure of MGLL can be determined
Data Source
Figure 1A~1C
Figure 1C
Figure 2A~2C
AI summary
A number of soluble engineered forms of MGLL that are suitable for high-throughput screening and protein crystallization, as well as a crystallized forms of monoacylglycerol lipase protein (MGLL) and descriptions of the X-ray diffraction patterns are disclosed. The engineered constructs of MGLL permit the expression and purification of protein suitable for crystallography or high-throughput screening and identification of ligands, which can function as active agents to MGLL. The X-ray diffraction patterns allow the three dimensional structure of MGLL to be determined at atomic resolution so that ligand binding sites on MGLL can be identified and the interactions of ligands with MGLL amino acid residues can be modeled. Models prepared using such maps permit the design of ligands which can function as active agents which include, but are not limited to, those that function as inhibitors of MGLL.